Consolidated Statements of Operations - USD ($) $ in Thousands		12 Months Ended
		Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
Research and development expenses	[1]	$ 47,110	$ 87,552
General and administrative expenses	[2]	22,061	39,466
Total operating expenses		69,171	127,018
Interest expense		4,377	7,530
Other income		(1,358)	(5,616)
Loss before income tax expense		(72,190)	(128,932)
Income tax expense		438	133
Net loss		$ (72,628)	$ (129,065)
Net loss per common share — basic and diluted (in shares)		$ (2.93)	$ (8.02)
Weighted average common shares outstanding - basic and diluted (in shares)		24,812,536	16,100,686
Research and development
Costs allocated		$ 0	$ (450)
General and Administrative
Costs allocated		$ 147	$ 2,898

[1] (1) Includes total costs (benefit) allocated from certain wholly owned subsidiaries of the Company's affiliate, Roivant Sciences Ltd., of $0 and $(450) for the years ended March 31, 2020 and 2019, respectively.

[2] (2) Includes total costs allocated from certain wholly owned subsidiaries of the Company's affiliate, Roivant Sciences Ltd., of $147 and $2,898 for the years ended March 31, 2020 and 2019, respectively.